Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 13Magnetic Resonance Spectroscopy 13lutetium Lu 177 dotatate 10cabozantinib 6Nivolumab 5X-Rays 4Ipilimumab 4Cisplatin 4pembrolizumab 3olaparib 3fludarabine 3Phantoms, Imaging 3Everolimus 3Etoposide 3Cyclophosphamide 3Carboplatin 3CTLA-4 Antigen 3gallium Ga 68 dotatate 2fluorodopa F 18 2aldesleukin 2Temozolomide 2Lutetium-177 2Lutetium 2Irinotecan 2Fluorodeoxyglucose F18 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2trametinib 1tipifarnib 1sodium thiosulfate 1selpercatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
BAY 1895344 × Endocrine × 30 days × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡